会议预告|《2026中国生物医药国际化发展蓝皮书》即将于沙利文生命科学新投资高峰论坛生物医药专场发布

The 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Conference (hereinafter referred to as "2026 Frost & Sullivan Summit" or "Conference"), organized by Frost & Sullivan, a world-leading growth consulting firm, will be held grandly in Shanghai from August 4-5, 2026. During the conference, a new investment forum for life sciences will be launched. The forum will feature three parallel sessions focusing on biomedicine, medical devices, and health technology, presenting cutting-edge topics and latest insights. With the core concept “Driving Change through Innovation, Staying Resilient and Achieving Long-Term Success”, the forum invites industry leaders, biomedicine and medical device companies, health technology firms, investment institutions, and professional service organizations to deeply discuss emerging trends in life sciences, innovative technologies, and global development paths, aiming to promote industrial advancement and global collaboration. The “2026 China Biopharmaceutical Internationalization Development Blue Book” will be released during the biomedicine session of the new investment forum for life sciences on August 5.

Host City: Shanghai, China

Date: August 4-5, 2026

Conference Scale: 5,000+

Conference Format: Offline + Online Live Streaming

Organizer: Frost & Sullivan

Scan the QR code to register immediately

Blue Book Release

The “2026 China Biopharmaceutical Internationalization Development Blue Book” will be released during the biomedicine session of the new investment forum for life sciences on August 5.

“Internationalization” of Chinese biopharmaceutical companies is an inevitable choice for China’s innovative drug industry after completing early capacity accumulation, as it actively participates in global industrial division of labor and seeks larger market opportunities and higher value realization paths. In the past, Chinese biopharmaceutical companies relied more on local clinical resources, engineer advantages, and rapid iteration capabilities to start their innovation journey. However, as local market competition intensifies, payment constraints increase, and there are more homogeneous products, internationalization becomes an important direction for companies to break through growth boundaries, verify innovation value, and enhance capital recognition. Meanwhile, global pharmaceutical companies are re-evaluating China’s innovative strength, considering Chinese companies as important research and development partners, asset sources, and industrial chain partners.

Under this context, Chinese biopharmaceutical companies are moving from “product internationalization” to “capability and system internationalization” through various methods such as overseas clinical development, international registration applications, licensing transactions, overseas production, and commercialization strategies. True internationalization requires companies to have globally competitive products, as well as comprehensive capabilities in clinical design, registration communication, quality systems, intellectual property, business cooperation, and cross-cultural management that align with international standards. How to identify reliable opportunities in changing global industrial patterns and convert Chinese innovation into global market value has become a core question for China’s biopharmaceutical industry as it enters a new stage.

Based on this, Frost & Sullivan releases the “2026 China Biopharmaceutical Internationalization Development Blue Book” to systematically outline the stage characteristics, driving factors, main paths, and future trends of internationalization development of Chinese biopharmaceutical companies, and to discuss the long-term value and development blueprint of China’s biopharmaceutical industry in global markets with industry participants, investors, and stakeholders.

Overview of Main Contents of the “2026 China Biopharmaceutical Internationalization Development Blue Book”

Analysis of the Background of China’s Biopharmaceutical Internationalization	Provides an overview of the current state of China’s biopharmaceutical industry and analyzes internal and external driving factors for internationalization development, such as the pressure of medical insurance negotiations and centralized procurement, significant improvements in China’s biopharmaceutical R&D capabilities and quality, and potential in overseas markets. Internationalization has become a strategic development path for Chinese biopharmaceutical companies.
General Overview of the History of Biopharmaceutical Internationalization	Outlines the development process of China’s biopharmaceutical internationalization, from active pharmaceutical ingredients to generic drugs, to the globalization of innovative drugs, and explains the characteristics, export scale, and representative events of different internationalization stages, thereby drawing up a roadmap for China’s biopharmaceutical internationalization.
Development and Trends of Internationalization of Active Pharmaceutical Ingredients and Generic Drugs	Analyzes the global market structure of active pharmaceutical ingredients and generic drugs, outlines the export scale, regional distribution, product category structure, and current status of internationalization of Chinese generic drugs, summarizes the competitive advantages of Chinese companies in cost, quality, registration, and supply chain, and predicts future internationalization trends based on representative cases.
Current Status and Trends of Internationalization of Innovative Drugs	Systematically analyzes the current status, main models, and development trends of internationalization of Chinese innovative drugs across different drug types such as antibodies, chemical drugs, peptides, and CGT. By using representative cases, it compares the applicable scenarios and advantages of overseas licensing, joint development, independent registration and marketing, NewCo, and commercialization partnerships. It also examines the core elements, main challenges, and future opportunities of internationalization of Chinese innovative drugs from aspects such as overseas clinical development, special regulatory qualifications, license-out transactions, overseas approval and marketing, regional access and distribution policies, and overseas team building.
Introduction to Internationalized/Planned to Be Internationalized Companies and Internationalization Service Providers	The blue book will include partner companies, presenting their business areas, pipeline layouts, technology platforms, and differentiated advantages. It will also show the internationalization development strategies, overseas layout, and practical experience of partner companies, highlighting their global competitive advantages and the core value of their internationalized or planned to be internationalized products. For internationalization service providers, the blue book will display their internationalization business content, internationalization service regions, and representative service company cases, showcasing the service highlights and advantages of internationalization service providers.